An Open-Label, Expanded Access Protocol for Patient With Sickle Cell Disease Who Have No Alternative Treatment Options
Latest Information Update: 19 Jul 2023
At a glance
- Drugs Voxelotor (Primary)
- Indications Sickle cell anaemia
- Focus Expanded access; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 23 Dec 2019 Status changed from recruiting to completed.
- 15 May 2019 New trial record